Chinese scientists fired after child dies in gene editing study: report

China flag against blue sky
Chinese authorities outlined actions they are taking to improve practices. (SW1994/Pixabay)

Chinese authorities have fired two researchers over their roles in the death of a child in a gene editing study, according to a report in Chinese state media.

The researchers were dismissed and barred from government science projects for five years, China Central Television (CCTV) reported Nov. 13. Authorities took the actions after finding the researchers failed to promptly report a preclinical safety signal, emphasize the risk of death in the informed consent form or disclose the death in a journal paper, according to CCTV. The probe also found fault with the ethics review process. 

Other findings included undisclosed conflicts of interest. Families gave the researchers money and gifts totaling about 1.1 million Chinese yuan ($160,000). The gifts, which were not disclosed in the research paper, included high-end liquor and electronic products, CCTV reported.

The findings triggered the dismissal of the person in charge of preclinical research and a key member of their team. Five other people received punishments ranging from demotions to administrative warnings, according to CCTV. 

Authorities outlined actions they are taking to improve practices. Multiple organizations must submit written self-examinations and take steps to rectify the failings identified in the investigation, CCTV said. Authorities plan to strengthen oversight of clinical trials involving new biomedical technologies, such as gene editing therapies, according to the article. 

The actions come as China implements new rules on investigator-initiated trials (IITs), which have enabled drug candidates to move quickly into early clinical development but raised questions about the adequacy of oversight and safety reporting. The revised rules limit which sites can run IITs and impose additional requirements on the studies. 

China implemented the new rules in May. Science and Retraction Watch reported the child’s death in July, triggering the investigation that led to the dismissals and other penalties. The child received a gene therapy to correct a genetic mutation that impaired brain development. 

In August, Stat uncovered that a young boy enrolled in HuidaGene Therapeutics’ IIT trial for Duchenne muscular dystrophy died last year of acute respiratory distress syndrome following administration of a CRISPR-based treatment. 

Together, the two incidents—both involving severe immune reactions to high-dose, viral vector-delivered gene therapies and a lack of disclosure—drew international scrutiny to what appeared to be systemic gaps in oversight and transparency within China’s IIT framework.